Comparison Of Post Operative Pain Relief In Patients Undergoing Laparoscopic General Surgery, with Bupivacaine as against methylene Blue with Bupivacaine.

Comparison Of Pain Relief In Tranversus Abdominus Plane Block In Patients Undergoing Laparoscopic General Surgery Using 20 Ml Of 0.25% Bupivacaine Verses 19 Ml Of 0.25% Bupivacaine And 1Ml Methylene Blue

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/12/048237

Enrollment

128

Registered

2022-12-19

Start date

Unknown

Completion date

Unknown

Last updated

2023-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K810- Acute cholecystitis Health Condition 2: K812- Acute cholecystitis with chronic cholecystitis Health Condition 3: K400- Bilateral inguinal hernia, with obstruction, without gangrene Health Condition 4: K819- Cholecystitis, unspecified Health Condition 5: K87- Disorders of gallbladder, biliarytract and pancreas in diseases classified elsewhere Health Condition 6: K571- Diverticular disease of small intestine without perforation or abscess Health Condition 7: K570- Diverti

Interventions

Intervention1: 0.25% Bupivacaine: 20 ml of 0.25% Bupivacaine in Tranversus Abdominus Plane Block block as a single injection, given under USG guidance. Control Intervention1: 0.25% Bupivacaine And Met

Eligibility

Inclusion criteria

Inclusion criteria: PATIENTS GIVING INFORMED VALID CONSENTS PATIENTS UNDERGOING LAPAROSCOPIC SURGERY UNDER GENERAL ANAESTHESIA

Exclusion criteria

Exclusion criteria: 1)PATIENTS UNWILLING TO GIVEN CONSENT 2) AGE LESS THAN 18 YEARS OR MORE THAN 70 YEARS 3) DOCUMENTED ALLERGY OR INTOLERANCE TO STUDY COMPOUND 4) ANY SEVERE PERI-OPERATIVE COMPLICATIONS 5) PATIENTS ON CHRONIC PAIN MEDICATIONS 6) INTRA-OPERATIVE CONVERSION FROM LAPAROSCOPIC TO OPEN 7) PREGNANCY OR LACTATING MOTHERS 8) CO-EXISTNG SEVERE CARDIOVASCULAR, NEUROLOGICAL, HEPATIC, RENAL OR ENDOCRINOLOGICAL DISTURBANCES.

Design outcomes

Primary

Measure	Time frame
To assess efficiency of Methylene blue as an adjuvant to LA in TAP block by assessing the VAS scale at different time intervals of 4,8,12, and 24 hours, post operatively.Timepoint: To assess efficiency of Methylene blue as an adjuvant to LA in TAP block by assessing the VAS scale at different time intervals of 4,8,12, and 24 hours, post operatively.	—

Secondary

Measure	Time frame
To evaluate the total analgesic requirement in the first 24 hours post-surgery of laparoscopic surgery under general anesthesia and the role of methylene blue to reduce the total requirement of rescue analgesiaTimepoint: 24 hours	—

Countries

India

Contacts

Public ContactEsha Pradeep Mhaskar

Sir H.N Reliance Foundation Hospital

Hemant.Mehta@rfhospital.org9820022260

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026